Therapy for alcoholic liver disease

World Journal of Gastroenterology

Volumn 20, Issue 9, 2014, Pages 2143-2158

  Jaurigue, Maryconi M ^a   Cappell, Mitchell S ^a,b  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

Author keywords

Alcoholic cirrhosis; Alcoholic hepatitis; Alcoholic liver disease; Alcoholic steatosis; Alcoholism; Corticosteroids; Liver disease; Liver transplantation; Pentoxifylline

Indexed keywords

ACAMPROSATE; BACLOFEN; CORTICOSTEROID; DISULFIRAM; NALTREXONE; PENTOXIFYLLINE; DRUGS USED IN THE TREATMENT OF ADDICTION;

ALCOHOL ABSTINENCE; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; ALCOHOLISM; ARTICLE; ASCITES; BACTERIAL PERITONITIS; DIET THERAPY; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE SEVERITY; ESOPHAGUS VARICES; HEPATIC ENCEPHALOPATHY; HEPATOPULMONARY SYNDROME; HEPATORENAL SYNDROME; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER TRANSPLANTATION; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARENTERAL NUTRITION; PORTOPULMONARY HYPERTENSION; PROGNOSIS; PROTEIN EXPRESSION; PROTHROMBIN TIME; QUALITY OF LIFE; SCORING SYSTEM; STOMACH VARICES; SURVIVAL RATE; ANIMAL; DISEASE COURSE; LIVER DISEASES, ALCOHOLIC; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ALCOHOL ABSTINENCE; ALCOHOL DETERRENTS; ANIMALS; DISEASE PROGRESSION; HUMANS; LIVER DISEASES, ALCOHOLIC; LIVER TRANSPLANTATION; PENTOXIFYLLINE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84895898644     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i9.2143     Document Type: Article

References (150)

1. World Health Organization. Global status report on alcohol and health. Geneva: World Health Organization, 2011: 286
2. Kim WR, Brown RS, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002; 36: 227-242 [PMID: 12085369 DOI: 10.1053/ jhep.2002.34734]
3. Paula H, Asrani SK, Boetticher NC, Pedersen R, Shah VH, Kim WR. Alcoholic liver disease-related mortality in the United States: 1980-2003. Am J Gastroenterol 2010; 105: 1782-1787 [PMID: 20179691 DOI: 10.1038/ajg.2010.46]
4. American Psychiatric Association. Alcohol Use Disorder. Diagnostic and Statistical Manual of Mental Disorders. Arlington, VA: American Psychiatric Publishing, 2013: 490-497
5. National Institute on Alcohol Abuse and Alcoholism. Rethinking Drinking: Alcohol and Your Health, 2010. Available from: URL: http://rethinkingdrinking.niaaa.nih.gov
6. Bellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, Saveria Crocè L, Sasso F, Pozzato G, Cristianini G, Brandi G. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 1997; 41: 845-850 [PMID: 9462221]
7. Becker U, Deis A, Sørensen TI, Grønbaek M, Borch-Johnsen K, Müller CF, Schnohr P, Jensen G. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology 1996; 23: 1025-1029 [PMID: 8621128 DOI: 10.1002/hep.510230513]
8. Tuyns AJ, Pequignot G. Greater risk of ascitic cirrhosis in females in relation to alcohol consumption. Int J Epidemiol 1984; 13: 53-57 [PMID: 6698704]
9. Ward RJ, Coutelle Ch. Women and alcohol susceptibility: could differences in alcohol metabolism predispose women to alcohol-related diseases? Arch Womens Ment Health 2003; 6: 231-238 [PMID: 14628174 DOI: 10.1007/s00737-003-0015-7]
10. Wagnerberger S, Schäfer C, Schwarz E, Bode C, Parlesak A. Is nutrient intake a gender-specific cause for enhanced susceptibility to alcohol-induced liver disease in women? Alcohol Alcohol 2008; 43: 9-14 [PMID: 18003723 DOI: 10.1093/ alcalc/agm161]
11. Frezza M, di Padova C, Pozzato G, Terpin M, Baraona E, Lieber CS. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med 1990; 322: 95-99 [PMID: 2248624 DOI: 10.1056/NEJM199001113220205]
12. Seth D, Haber PS, Syn WK, Diehl AM, Day CP. Pathogenesis of alcohol-induced liver disease: classical concepts and recent advances. J Gastroenterol Hepatol 2011; 26: 1089-1105 [PMID: 21545524 DOI: 10.1111/j.1440-1746.2011.06756.x]
13. Orman ES, Odena G, Bataller R. Alcoholic liver disease: pathogenesis, management, and novel targets for therapy. J Gastroenterol Hepatol 2013; 28 Suppl 1: 77-84 [PMID: 23855300 DOI: 10.1111/jgh.12030]
14. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011; 141: 1572-1585 [PMID: 21920463 DOI: 10.1053/j.gastro.2011.09.002]
15. Park EY, Lim MK, Oh JK, Cho H, Bae MJ, Yun EH, Kim DI, Shin HR. Independent and supra-additive effects of alcohol consumption, cigarette smoking, and metabolic syndrome on the elevation of serum liver enzyme levels. PLoS One 2013; 8: e63439 [PMID: 23667618 DOI: 10.1371/journal.pone.0063439]
16. Taniai M, Hashimoto E, Tokushige K, Kodama K, Kogiso T, Torii N, Shiratori K. Roles of gender, obesity, and lifestylerelated diseases in alcoholic liver disease: Obesity does not influence the severity of alcoholic liver disease. Hepatol Res 2012; 42: 359-367 [PMID: 22150916 DOI: 10.1111/j.1872-034X.2011.00935.x]
17. Raynard B, Balian A, Fallik D, Capron F, Bedossa P, Chaput J, Naveau S. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002; 35: 635-638 [PMID: 11870378 DOI: 10.1053/jhep.2002.31782]
18. Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput J. Excess weight risk factor for alcoholic liver disease. Hepatology 1997; 25: 108-111 [PMID: 8985274 DOI: 10.1002/hep.510250120]
19. Fletcher LM, Halliday JW, Powell LW. Interrelationships of alcohol and iron in liver disease with particular reference to the iron-binding proteins, ferritin and transferrin. J Gastroenterol Hepatol 1999; 14: 202-214 [PMID: 10197487]
20. Schmidt CS, Schön D, Schulte B, Lüth S, Polywka S, Reimer J. Viral hepatitis in alcohol-dependent inpatients: prevalence, risk factors, and treatment uptake. J Addict Med 2013; 7: 417-421 [PMID: 24189174 DOI: 10.1097/ADM.0b013e3182a50817]
21. Zhang M, Wu R, Jiang J, Minuk GY, Niu J. The presence of hepatitis B core antibody is associated with more advanced liver disease in alcoholic patients with cirrhosis. Alcohol 2013; 47: 553-558 [PMID: 24041840 DOI: 10.1016/j.alcohol.2013.07.003]
22. Mann RE, Smart RG, Govoni R. The epidemiology of alcoholic liver disease. Alcohol Res Health 2003; 27: 209-219 [PMID: 15535449]
23. MacSween RN, Burt AD. Histologic spectrum of alcoholic liver disease. Semin Liver Dis 1986; 6: 221-232 [PMID: 3022386 DOI: 10.1055/s-2008-1040605]
24. O'Shea RS, McCullough AJ. Treatment of alcoholic hepatitis. Clin Liver Dis 2005; 9: 103-134 [PMID: 15763232 DOI: 10.1016/j.cld.2004.11.004]
25. Pateria P, de Boer B, MacQuillan G. Liver abnormalities in drug and substance abusers. Best Pract Res Clin Gastroenterol 2013; 27: 577-596 [PMID: 24090944 DOI: 10.1016/j.bpg.2013.08.001]
26. European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012; 57: 399-420 [PMID: 22633836 DOI: 10.1016/ j.jhep.2012.04.004]
27. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999; 94: 1018-1022 [PMID: 10201476 DOI: 10.1111/j.1572-0241.1999.01006.x]
28. Zhou SL, Gordon RE, Bradbury M, Stump D, Kiang CL, Berk PD. Ethanol up-regulates fatty acid uptake and plasma membrane expression and export of mitochondrial aspartate aminotransferase in HepG2 cells. Hepatology 1998; 27: 1064-1074 [PMID: 9537447 DOI: 10.1002/hep.510270423]
29. Tchelepi H, Ralls PW, Radin R, Grant E. Sonography of diffuse liver disease. J Ultrasound Med 2002; 21: 1023-1032; quiz 1033-1034 [PMID: 12216750]
30. Attali P, Ink O, Pelletier G, Vernier C, Jean F, Moulton L, Etienne JP. Dupuytren's contracture, alcohol consumption, and chronic liver disease. Arch Intern Med 1987; 147: 1065-1067 [PMID: 3592873]
31. Okazaki H, Ito K, Fujita T, Koike S, Takano K, Matsunaga N. Discrimination of alcoholic from virus-induced cirrhosis on MR imaging. AJR Am J Roentgenol 2000; 175: 1677-1681 [PMID: 11090403 DOI: 10.2214/ajr.175.6.1751677]
32. O'Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Am J Gastroenterol 2010; 105: 14-32; quiz 33 [PMID: 19904248 DOI: 10.1038/ajg.2009.593]
33. Liangpunsakul S, Crabb DW. Alcoholic liver disease. Textbook of Gastroenterology. 5th ed. Oxford: Blackwell Publishing Ltd, 2009: 2247-2273
34. Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: an update. Hepatology 2008; 47: 2089-2111 [PMID: 18506894 DOI: 10.1002/hep.22261]
35. Mani H, Kleiner DE. Liver biopsy findings in chronic hepatitis B. Hepatology 2009; 49: S61-S71 [PMID: 19399798 DOI: 10.1002/hep.22930]
36. Rofsky NM, Fleishaker H. CT and MRI of diffuse liver disease. Semin Ultrasound CT MR 1995; 16:16-33 [PMID: 7718279]
37. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-649 [PMID: 4541913]
38. Lucey MR, Brown KA, Everson GT, Fung JJ, Gish R, Keeffe EB, Kneteman NM, Lake JR, Martin P, McDiarmid SV, Rakela J, Shiffman ML, So SK, Wiesner RH. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg 1997; 3: 628-637 [PMID: 9404965]
39. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, Lake J, Howard T, Merion RM, Wolfe RA, Krom R. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-96 [PMID: 12512033 DOI: 10.1053/gast.2003.50016]
40. Freeman RB, Wiesner RH, Harper A, McDiarmid SV, Lake J, Edwards E, Merion R, Wolfe R, Turcotte J, Teperman L. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl 2002; 8: 851-858 [PMID: 12200791 DOI: 10.1053/jlts.2002.35927]
41. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864-871 [PMID: 10733541 DOI: 10.1053/ he.2000.5852]
42. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-470 [PMID: 11172350 DOI: 10.1053/jhep.2001.22172]
43. Al Sibae MR, Cappell MS. Accuracy of MELD scores in predicting mortality in decompensated cirrhosis from variceal bleeding, hepatorenal syndrome, alcoholic hepatitis, or acute liver failure as well as mortality after non-transplant surgery or TIPS. Dig Dis Sci 2011; 56: 977-987 [PMID: 20844956 DOI: 10.1007/s10620-010-1390-3]
44. The MELD Model 2013. Available from: URL: http://www. mayoclinic.org/meld/mayomodel5.html
45. Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, Edwards E, Therneau TM. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008; 359: 1018-1026 [PMID: 18768945 DOI: 10.1056/NEJMoa0801209]
46. Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, Benson J, Therneau T, Kremers W, Wiesner R, Kamath P, Klintmalm G. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006; 130: 1652-1660 [PMID: 16697729 DOI: 10.1053/j.gastro.2006.02.010]
47. Maddrey WC, Boitnott JK, Bedine MS, Weber FL, Mezey E, White RI. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978; 75: 193-199 [PMID: 352788]
48. Carithers RL, Herlong HF, Diehl AM, Shaw EW, Combes B, Fallon HJ, Maddrey WC. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med 1989; 110: 685-690 [PMID: 2648927]
49. Ramond MJ, Poynard T, Rueff B, Mathurin P, Théodore C, Chaput JC, Benhamou JP. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992; 326: 507-512 [PMID: 1531090 DOI: 10.1056/ NEJM199202203260802]
50. Mendenhall CL, Anderson S, Garcia-Pont P, Goldberg S, Kiernan T, Seeff LB, Sorrell M, Tamburro C, Weesner R, Zetterman R. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N Engl J Med 1984; 311: 1464-1470 [PMID: 6390194 DOI: 10.1056/NEJM198412063112302]
51. Theodossi A, Eddleston AL, Williams R. Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut 1982; 23: 75-79 [PMID: 7035299]
52. Depew W, Boyer T, Omata M, Redeker A, Reynolds T. Double-blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy. Gastroenterology 1980; 78: 524-529 [PMID: 6985881]
53. Shumaker JB, Resnick RH, Galambos JT, Makopour H, Iber FL. A controlled trial of 6-methylprednisolone in acute alcoholic hepatitis. With a note on published results in encephalopathic patients. Am J Gastroenterol 1978; 69: 443-449 [PMID: 356593]
54. Blitzer BL, Mutchnick MG, Joshi PH, Phillips MM, Fessel JM, Conn HO. Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double-blind randomized study. Am J Dig Dis 1977; 22: 477-484 [PMID: 326034]
55. Mathurin P, Mendenhall CL, Carithers RL, Ramond MJ, Maddrey WC, Garstide P, Rueff B, Naveau S, Chaput JC, Poynard T. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002; 36: 480-487 [PMID: 11943418]
56. Forrest EH, Evans CD, Stewart S, Phillips M, Oo YH, McAvoy NC, Fisher NC, Singhal S, Brind A, Haydon G, O'Grady J, Day CP, Hayes PC, Murray LS, Morris AJ. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005; 54: 1174-1179 [PMID: 16009691 DOI: 10.1136/ gut.2004.050781]
57. Dominguez M, Rincón D, Abraldes JG, Miquel R, Colmenero J, Bellot P, García-Pagán JC, Fernández R, Moreno M, Bañares R, Arroyo V, Caballería J, Ginès P, Bataller R. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol 2008; 103: 2747-2756 [PMID: 18721242 DOI: 10.1111/j.1572-0241.2008.02104.x]
58. Lille Model 2013. Available from: URL: http://www.lillemodel. com/score.asp?score=lillept
59. Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, Dharancy S, Texier F, Hollebecque A, Serfaty L, Boleslawski E, Deltenre P, Canva V, Pruvot FR, Mathurin P. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007; 45: 1348-1354 [PMID: 17518367 DOI: 10.1002/hep.21607]
60. Pessione F, Ramond MJ, Peters L, Pham BN, Batel P, Rueff B, Valla DC. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int 2003; 23: 45-53 [PMID: 12640727]
61. Borowsky SA, Strome S, Lott E. Continued heavy drinking and survival in alcoholic cirrhotics. Gastroenterology 1981; 80: 1405-1409 [PMID: 6971772]
62. Powell WJ Jr, Klatskin G. Duration of survival in patients with Laennec's cirrhosis: Influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease. Am J Med 1968; 44: 406-420 [PMID: 5641303 DOI: 10.1016/0002-9343(68)90111-3]
63. Brunt PW, Kew MC, Scheuer PJ, Sherlock S. Studies in alcoholic liver disease in Britain. I. Clinical and pathological patterns related to natural history. Gut 1974; 15: 52-58 [PMID: 4362373]
64. Muntaner L, Altamirano JT, Augustin S, González A, Esteban R, Guardia J, Genescà J. High doses of beta-blockers and alcohol abstinence improve long-term rebleeding and mortality in cirrhotic patients after an acute variceal bleeding. Liver Int 2010; 30: 1123-1130 [PMID: 20536715 DOI: 10.1111/ j.1478-3231.2010.02287.x]
65. Xie YD, Feng B, Gao Y, Wei L. Effect of abstinence from alcohol on survival of patients with alcoholic cirrhosis: A systematic review and meta-analysis. Hepatol Res 2013; Epub ahead of print [PMID: 23607793 DOI: 10.1111/hepr.12131]
66. Luca A, García-Pagán JC, Bosch J, Feu F, Caballería J, Groszmann RJ, Rodés J. Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis. Gastroenterology 1997; 112: 1284-1289 [PMID: 9098014]
67. Bardou-Jacquet E, Legros L, Soro D, Latournerie M, Guillygomarc'h A, Le Lan C, Brissot P, Guyader D, Moirand R. Effect of alcohol consumption on liver stiffness measured by transient elastography. World J Gastroenterol 2013; 19: 516-522 [PMID: 23382630 DOI: 10.3748/wjg.v19.i4.516]
68. Gelsi E, Dainese R, Truchi R, Mariné-Barjoan E, Anty R, Autuori M, Burroni S, Vanbiervliet G, Evesque L, Cherikh F, Tran A. Effect of detoxification on liver stiffness assessed by Fibroscan ® in alcoholic patients. Alcohol Clin Exp Res 2011; 35: 566-570 [PMID: 21143253 DOI: 10.1111/j.1530-0277.2010.01374.x]
69. Trabut JB, Thépot V, Nalpas B, Lavielle B, Cosconea S, Corouge M, Vallet-Pichard A, Fontaine H, Mallet V, Sogni P, Pol S. Rapid decline of liver stiffness following alcohol withdrawal in heavy drinkers. Alcohol Clin Exp Res 2012; 36: 1407-1411 [PMID: 22404692 DOI: 10.1111/j.1530-0277.2012.01737.x]
70. Murray KF, Carithers RL. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology 2005; 41: 1407-1432 [PMID: 15880505 DOI: 10.1002/hep.20704]
71. Matching Alcoholism Treatments to Client Heterogeneity: Project MATCH posttreatment drinking outcomes. J Stud Alcohol 1997; 58: 7-29 [PMID: 8979210]
72. Nowinski J, Baker S, Carroll K. Twelve Step Facilitation Therapy Manual: A clinical guide for therapists treating individuals with alcohol abuse and dependence. Rockville, Maryland: National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Health (NIH). Project MATCH Monograph Series 1992. Volume 1. Available from: URL: http://lib.adai.washington.edu/pubs/match1/ match1part1.pdf
73. Kadden R, Carroll K, Donovan D, Cooney N, Monti P, Abrams D, Litt M, Hester R. Cognitive-Behavior Coping Skills Therapy Manual: A clinical research guide for therapists treating individuals with alcohol abuse and dependence. Rockville, Maryland: National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Health (NIH). Project MATCH Monograph Series 1992. Volume 3. Available from: URL: http://pubs.niaaa.nih.gov/publications/ MATCHSeries3/Project%20MATCH%20Vol_3.pdf
74. Miller W, Zweben A, DiClemente C, Rychtarik R. Motivational Enhancement Therapy Manual: A clinical research guide for therapists treating individuals with alcohol abuse and dependence. Rockville, Maryland: National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Health (NIH). Project MATCH Monograph Series 1992. Volume 2. Available from: URL: http://casaa.unm.edu/ download/MET.pdf
75. Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, James KE, Lacoursiere RB, Lee KK, Lowenstam I. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA 1986; 256: 1449-1455 [PMID: 3528541]
76. Björnsson E, Nordlinder H, Olsson R. Clinical characteristics and prognostic markers in disulfiram-induced liver injury. J Hepatol 2006; 44: 791-797 [PMID: 16487618 DOI: 10.1016/ j.jhep.2005.12.016]
77. Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2010; (12): CD001867 [PMID: 21154349]
78. Jarosz J, Miernik K, Wa{ogonek}chal M, Walczak J, Krumpl G. Naltrexone (50 mg) plus psychotherapy in alcohol-dependent patients: a meta-analysis of randomized controlled trials. Am J Drug Alcohol Abuse 2013; 39: 144-160 [PMID: 23721530 DOI: 10.3109/00952990.2013.796961]
79. Pettinati HM, Gastfriend DR, Dong Q, Kranzler HR, O' Malley SS. Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients. Alcohol Clin Exp Res 2009; 33: 350-356 [PMID: 19053979 DOI: 10.1111/ j.1530-0277.2008.00843.x]
80. Tetrault JM, Tate JP, McGinnis KA, Goulet JL, Sullivan LE, Bryant K, Justice AC, Fiellin DA. Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone. Alcohol Clin Exp Res 2012; 36: 318-324 [PMID: 21797892 DOI: 10.1111/j.1530-0277.2011.01601.x]
81. Rösner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev 2010; (9): CD004332 [PMID: 20824837]
82. Mason BJ, Lehert P. Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data. Alcohol Clin Exp Res 2012; 36: 497-508 [PMID: 21895717 DOI: 10.1111/j.1530-0277.2011.01616.x]
83. Mason BJ, Goodman AM, Chabac S, Lehert P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res 2006; 40: 383-393 [PMID: 16546214 DOI: 10.1016/j.jpsychires.2006.02.002]
84. Baltieri DA, De Andrade AG. Acamprosate in alcohol dependence: a randomized controlled efficacy study in a standard clinical setting. J Stud Alcohol 2004; 65: 136-139 [PMID: 15000513]
85. Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 2004; 28: 51-63 [PMID: 14745302 DOI: 10.1097/01. ALC.0000108656.81563.05]
86. Palmer AJ, Neeser K, Weiss C, Brandt A, Comte S, Fox M. The long-term cost-effectiveness of improving alcohol abstinence with adjuvant acamprosate. Alcohol Alcohol 2000; 35: 478-492 [PMID: 11022023]
87. Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, Agabio R, Colombo G, Gessa GL, Gasbarrini G. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 2002; 37: 504-508 [PMID: 12217947]
88. Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, Abenavoli L, D'Angelo C, Caputo F, Zambon A, Haber PS, Gasbarrini G. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007; 370: 1915-1922 [PMID: 18068515 DOI: 10.1016/S0140-6736(07)61814-5]
89. Addolorato G, Leggio L, Ferrulli A, Cardone S, Bedogni G, Caputo F, Gasbarrini G, Landolfi R. Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol 2011; 46: 312-317 [PMID: 21414953 DOI: 10.1093/alcalc/agr017]
90. Leggio L, Ferrulli A, Zambon A, Caputo F, Kenna GA, Swift RM, Addolorato G. Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection. Addict Behav 2012; 37: 561-564 [PMID: 22244707 DOI: 10.1016/j.addbeh.2011.12.010]
91. Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Flannery BA. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 2010; 34: 1849-1857 [PMID: 20662805 DOI: 10.1111/j.1530-0277.2010.01273.x]
92. McClain CJ, Barve SS, Barve A, Marsano L. Alcoholic liver disease and malnutrition. Alcohol Clin Exp Res 2011; 35: 815-820 [PMID: 21284673 DOI: 10.1111/j.1530-0277.2010.01405.x]
93. Tsiaousi ET, Hatzitolios AI, Trygonis SK, Savopoulos CG. Malnutrition in end stage liver disease: recommendations and nutritional support. J Gastroenterol Hepatol 2008; 23: 527-533 [PMID: 18397483 DOI: 10.1111/j.1440-1746.2008.05369.x]
94. Huisman EJ, Trip EJ, Siersema PD, van Hoek B, van Erpecum KJ. Protein energy malnutrition predicts complications in liver cirrhosis. Eur J Gastroenterol Hepatol 2011; 23: 982-989 [PMID: 21971339 DOI: 10.1097/MEG.0b013e32834aa4bb]
95. Koretz RL, Avenell A, Lipman TO. Nutritional support for liver disease. Cochrane Database Syst Rev 2012; 5: CD008344 [PMID: 22592729 DOI: 10.1002/14651858.CD008344.pub2]
96. Plauth M, Cabré E, Riggio O, Assis-Camilo M, Pirlich M, Kondrup J, Ferenci P, Holm E, Vom Dahl S, Müller MJ, Nolte W. ESPEN Guidelines on Enteral Nutrition: Liver disease. Clin Nutr 2006; 25: 285-294 [PMID: 16707194 DOI: 10.1016/ j.clnu.2006.01.018]
97. Plauth M, Cabré E, Campillo B, Kondrup J, Marchesini G, Schütz T, Shenkin A, Wendon J. ESPEN Guidelines on Parenteral Nutrition: hepatology. Clin Nutr 2009; 28: 436-444 [PMID: 19520466 DOI: 10.1016/j.clnu.2009.04.019]
98. Poh Z, Chang PE. A current review of the diagnostic and treatment strategies of hepatic encephalopathy. Int J Hepatol 2012; 2012: 480309 [PMID: 23133760 DOI: 10.1155/2012/480309]
99. Mathurin P, O'Grady J, Carithers RL, Phillips M, Louvet A, Mendenhall CL, Ramond MJ, Naveau S, Maddrey WC, Morgan TR. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011; 60: 255-260 [PMID: 20940288 DOI: 10.1136/gut.2010.224097]
100. Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C. Systematic review: glucocorticosteroids for alcoholic hepatitis--a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther 2008; 27: 1167-1178 [PMID: 18363896 DOI: 10.1111/ j.1365-2036.2008.03685.x]
101. Christensen E, Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables. Gut 1995; 37: 113-118 [PMID: 7672658]
102. Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med 1990; 113: 299-307 [PMID: 2142869]
103. Stewart LA, Parmar MK. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 1993; 341: 418-422 [PMID: 8094183]
104. Mathurin P, Duchatelle V, Ramond MJ, Degott C, Bedossa P, Erlinger S, Benhamou JP, Chaput JC, Rueff B, Poynard T. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology 1996; 110: 1847-1853 [PMID: 8964410]
105. Kwon HJ, Won YS, Park O, Feng D, Gao B. Opposing effects of prednisolone treatment on T/NKT cell-and hepatotoxinmediated hepatitis in mice. Hepatology 2013; Epub ahead of print [PMID: 24115096 DOI: 10.1002/hep.26748]
106. Louvet A, Wartel F, Castel H, Dharancy S, Hollebecque A, Canva-Delcambre V, Deltenre P, Mathurin P. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology 2009; 137: 541-548 [PMID: 19445945 DOI: 10.1053/j.gastro.2009.04.062]
107. Tyagi P, Sharma P, Sharma BC, Puri AS, Kumar A, Sarin SK. Prevention of hepatorenal syndrome in patients with cirrhosis and ascites: a pilot randomized control trial between pentoxifylline and placebo. Eur J Gastroenterol Hepatol 2011; 23: 210-217 [PMID: 21285885 DOI: 10.1097/MEG.0b013e3283435d76]
108. Sztrymf B, Rabiller A, Nunes H, Savale L, Lebrec D, Le Pape A, de Montpreville V, Mazmanian M, Humbert M, Hervé P. Prevention of hepatopulmonary syndrome and hyperdynamic state by pentoxifylline in cirrhotic rats. Eur Respir J 2004; 23: 752-758 [PMID: 15176692]
109. Sidhu SS, Goyal O, Singla M, Bhatia KL, Chhina RS, Sood A. Pentoxifylline in severe alcoholic hepatitis: a prospective, randomised trial. J Assoc Physicians India 2012; 60: 20-22 [PMID: 23029716]
110. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-1648 [PMID: 11113085]
111. Parker R, Armstrong MJ, Corbett C, Rowe IA, Houlihan DD. Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis. Aliment Pharmacol Ther 2013; 37: 845-854 [PMID: 23489011 DOI: 10.1111/apt.12279]
112. Fernández-Rodríguez CM, Lledó JL, López-Serrano P, Gutiérrez ML, Alonso S, Pérez-Fernández MT, Fernández Gil M, Pazos R, Tolon R, Hernández T, Sanz P. [Effect of pentoxifylline on survival, cardiac function and both portal and systemic hemodynamics in advanced alcoholic cirrhosis--a randomized double-blind placebo-controlled trial]. Rev Esp Enferm Dig 2008; 100: 481-489 [PMID: 18942901]
113. Whitfield K, Rambaldi A, Wetterslev J, Gluud C. Pentoxifylline for alcoholic hepatitis. Cochrane Database Syst Rev 2009; (4): CD007339 [PMID: 19821406]
114. Sidhu SS, Goyal O, Singla P, Gupta D, Sood A, Chhina RS, Soni RK. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Dig Dis Sci 2012; 57: 1664-1671 [PMID: 22388710 DOI: 10.1007/s10620-012-2097-4]
115. Mathurin P, Louvet A, Duhamel A, Nahon P, Carbonell N, Boursier J, Anty R, Diaz E, Thabut D, Moirand R, Lebrec D, Moreno C, Talbodec N, Paupard T, Naveau S, Silvain C, Pageaux GP, Sobesky R, Canva-Delcambre V, Dharancy S, Salleron J, Dao T. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA 2013; 310: 1033-1041 [PMID: 24026598 DOI: 10.1001/jama.2013.276300]
116. Matas AJ, Smith JM, Skeans MA, Lamb KE, Gustafson SK, Samana CJ, Stewart DE, Snyder JJ, Israni AK, Kasiske BL. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR) 2011 Data Report. Am J Transpl 2013; 13 (suppl 1): 11-46
117. Burra P, Senzolo M, Adam R, Delvart V, Karam V, Germani G, Neuberger J. Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). Am J Transplant 2010; 10: 138-148 [PMID: 19951276 DOI: 10.1111/j.1600-6143.2009.02869.x]
118. Mackie J, Groves K, Hoyle A, Garcia C, Garcia R, Gunson B, Neuberger J. Orthotopic liver transplantation for alcoholic liver disease: a retrospective analysis of survival, recidivism, and risk factors predisposing to recidivism. Liver Transpl 2001; 7: 418-427 [PMID: 11349262 DOI: 10.1053/jlts.2001.23789]
119. Schmeding M, Heidenhain C, Neuhaus R, Neuhaus P, Neumann UP. Liver transplantation for alcohol-related cirrhosis: a single centre long-term clinical and histological follow-up. Dig Dis Sci 2011; 56: 236-243 [PMID: 20499174 DOI: 10.1007/ s10620-010-1281-7]
120. Hartl J, Scherer MN, Loss M, Schnitzbauer A, Farkas S, Baier L, Szecsey A, Schoelmerich J, Schlitt HJ, Kirchner GI. Strong predictors for alcohol recidivism after liver transplantation: non-acceptance of the alcohol problem and abstinence of < 3 months. Scand J Gastroenterol 2011; 46: 1257-1266 [PMID: 21815863 DOI: 10.3109/00365521.2011.603160]
121. Kumar S, Stauber RE, Gavaler JS, Basista MH, Dindzans VJ, Schade RR, Rabinovitz M, Tarter RE, Gordon R, Starzl TE. Orthotopic liver transplantation for alcoholic liver disease. Hepatology 1990; 11: 159-164 [PMID: 2307394]
122. Herrero JI. De novo malignancies following liver transplantation: Impact and recommendations. Liver Transpl 2009; 15: S90-S94 [PMID: 19877025 DOI: 10.1002/lt.21898]
123. Jonas S, Rayes N, Neumann U, Neuhaus R, Bechstein WO, Guckelberger O, Tullius SG, Serke S, Neuhaus P. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 1997; 80: 1141-1150 [PMID: 9305716]
124. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: An update. Hepatology 2011; 53: 1020-1022 [DOI: 10.1002/ hep.24199]
125. Hepatology Centers of Educational Expertise. Hepatic encephalopathy update: Reports from ACG 2012 and the Liver Meeting 2012. Available from: URL: http://www. chronicliverdisease.org/disease_focus/enewsletters/HepCof EE_eNewsletter_Reports_From_ACG2012_2013_ol.pdf
126. Blei AT, Córdoba J. Hepatic encephalopathy. Am J Gastroenterol 2001; 96: 1968-1976 [PMID: 11467622 DOI: 10.1111/ j.1572-0241.2001.03964.x]
127. Garcia-Tsao G, Lim JK. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol 2009; 104: 1802-1829 [PMID: 19455106 DOI: 10.1038/ajg.2009.191]
128. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007; 46: 922-938 [PMID: 17879356 DOI: 10.1002/hep.21907]
129. Runyon B. AASLD Practice Guideline: Management of Adult Patients with Ascites Due to Cirrhosis: Update 2012. Available from: URL: http://www.aasld.org/practiceguidelines/ Documents/ascitesupdate2013.pdf
130. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397-417 [PMID: 20633946 DOI: 10.1016/j.jhep.2010.05.004]
131. Rodríguez-Roisin R, Krowka MJ, Hervé P, Fallon MB. Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J 2004; 24: 861-880 [PMID: 15516683 DOI: 10.1183/09031936.04.00010 904]
132. Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 1992; 117: 215-220 [PMID: 1616215]
133. Perera E, Bhatt S, Dogra VS. Complications of denver shunt. J Clin Imaging Sci 2011; 1: 6 [PMID: 21915387]
134. Sugawara S, Sone M, Arai Y, Sakamoto N, Aramaki T, Sato Y, Inaba Y, Takeuchi Y, Ueno T, Matsueda K, Moriguchi M, Tsushima T. Radiological insertion of Denver peritoneovenous shunts for malignant refractory ascites: a retrospective multicenter study (JIVROSG-0809). Cardiovasc Intervent Radiol 2011; 34: 980-988 [PMID: 21191592 DOI: 10.1007/s00270-010-0057-y]
135. White MA, Agle SC, Padia RK, Zervos EE. Denver peritoneovenous shunts for the management of malignant ascites: a review of the literature in the post LeVeen Era. Am Surg 2011; 77: 1070-1075 [PMID: 21944526]
136. Desai AP, Reau N, Reddy KG, Te HS, Mohanty S, Satoskar R, Devoss A, Jensen D. Persistent spontaneous bacterial peritonitis: a common complication in patients with spontaneous bacterial peritonitis and a high score in the model for endstage liver disease. Therap Adv Gastroenterol 2012; 5: 275-283 [PMID: 22973414 DOI: 10.1177/1756283X11417037]
137. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362: 1071-1081 [PMID: 20335583 DOI: 10.1056/NEJMoa0907893]
138. Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, Ring-Larsen H, Schölmerich J. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23: 164-176 [DOI: 10.1002/hep.510230122]
139. Rodríguez-Roisin R, Agustí AG, Roca J. The hepatopulmonary syndrome: new name, old complexities. Thorax 1992; 47: 897-902 [PMID: 1465744]
140. Krowka MJ. Portopulmonary hypertension. Semin Respir Crit Care Med 2012; 33: 17-25 [PMID: 22447257 DOI: 10.1055/ s-0032-1301731]
141. Stevenson M, Lloyd-Jones M, Morgan MY, Wong R. Noninvasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation. Health Technol Assess 2012; 16: 1-174 [PMID: 22333291 DOI: 10.3310/ hta16040]
142. Rambaldi A, Jacobs BP, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev 2007; (4): CD003620 [PMID: 17943794 DOI: 10.1002/14651858.CD003620.pub3]
143. Rambaldi A, Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. Cochrane Database Syst Rev 2006; (2): CD002235 [PMID: 16625556 DOI: 10.1002/14651858.CD002235.pub2]
144. Spahr L, Rubbia-Brandt L, Frossard JL, Giostra E, Rougemont AL, Pugin J, Fischer M, Egger H, Hadengue A. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 2002; 37: 448-455 [PMID: 12217597]
145. Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, Davion T, Oberti F, Broët P, Emilie D. A doubleblind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004; 39: 1390-1397 [PMID: 15122768 DOI: 10.1002/hep.20206]
146. Reep GL, Soloway RD. Recent and currently emerging medical treatment options for the treatment of alcoholic hepatitis. World J Hepatol 2011; 3: 211-214 [PMID: 21954409 DOI: 10.4254/wjh.v3.i8.211]
147. Kong X, Feng D, Mathews S, Gao B. Hepatoprotective and anti-fibrotic functions of interleukin-22: therapeutic potential for the treatment of alcoholic liver disease. J Gastroenterol Hepatol 2013; 28 Suppl 1: 56-60 [PMID: 23855297 DOI: 10.1111/jgh.12032]
148. Jiang R, Tan Z, Deng L, Chen Y, Xia Y, Gao Y, Wang X, Sun B. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology 2011; 54: 900-909 [PMID: 21674558 DOI: 10.1002/hep.24486]
149. Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis DG, Ladas SD. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol 2013; 28: 450-455 [PMID: 23216382 DOI: 10.1111/jgh.12070]
150. Singal AK, Kamath PS, Gores GJ, Shah VH. Alcoholic Hepatitis: Current Challenges and Future Directions. Clin Gastroenterol Hepatol 2013; pii: S1542-3565(13)00872-0 [PMID: 23811249 DOI: 10.1016/j.cgh.2013.06.013]